Business
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"text","content":"IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN). Eledon plans to open U.S. sites under this IND as part of its ongoing global Phase 2a clinical trial evaluating tegoprubart for the treatment of IgAN. Including the U.S., the trial has now received regulatory clearances in 10 countries with plans to expand the study in up to 2 additional countries, including China. Multiple patients in the Phase 2a study have begun receiving treatment with tegoprubart. IgAN, the most common primary glomerulonephritis disease, affects approximately 150,000 Americans and is characterized by gradual, progressive kidney function deterioration which can potentially lead to End-Stage Renal Disease (“ESRD”), dialysis, renal transplant, and death. Leakage of blood proteins into the urine, or proteinuria, is a clinical sign of IgAN, and the severity of proteinuria predicts the rate of progression to ESRD. In addition, reducing proteinuria has been shown to delay progression to ESRD. Current standard of care with ACEi/ARB therapies and budesonide are effective in a subset of patients with IgAN, but many patients on these therapies continue to have progressive disease and continue to be at risk of ESRD. The global multicenter, open-label study is enrolling up to 21 patients in each of two dose cohorts with confirmed diagnosis of IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening. The study will evaluate the safety and efficacy of tegoprubart, with the primary endpoint being change from baseline in urine protein (assessed as urine protein to creatinine ratio) after 24 weeks of therapy. Dosing will continue through 96 weeks, and change from baseline in eGFR slope will be assessed at 96 weeks. Preclinical evidence has demonstrated that blocking CD40L signaling can improve proteinuria, reduce autoantibodies, decrease immune cell infiltration into the kidneys, and improve survival. About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501) Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also call...